Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Announces June 2020 as the Largest Sales Bookings Month in Company History

SAN DIEGOJuly 6, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® Mexico had its largest-ever sales bookings month in the Company’s history in June 2020.

Raul Elizalde, who was just promoted from President of Latin American operations to co-CEO of our global operations, has done a tremendous job growing our sales and operations in Latin America as proven by June’s success,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are fortunate and thankful to have many loyal customers who continue to purchase our high-quality hemp CBD products.”

In addition to the Company’s sales booking success in June, its co-CEO Raul Elizalde was invited to speak on Endeavor’s expert panel entitled “Cannabis in Mexico: The Debate and Opportunities for an Emerging Industry” where he discussed the legislative process required to legalize cannabis in Mexico, the agricultural and business opportunities the industry could bring to the country’s economy, and the potential economic and social transformation that may follow.

“The HempMeds Mexico team has tremendous talent and perseverance — it’s inspiring to witness their success,” said HempMeds® co-CEO Raul Elizalde. “The cannabis industry is resilient and this great financial update showcases that our portfolio of companies is well-positioned for continued growth despite the many challenges the world is facing today.”

Accomplishments also include the Company obtaining positive news coverage in several national and international news outlets including El EconomistaHora CeroFundacion Loto Rojo and several others.

About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® BiotechnologiesInc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of BrazilMexicoArgentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at or by visiting To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.


Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 858-264-6600

[email protected]

Investor Relations Contact:

P. (858) 283-4016

[email protected]